CharlieeMungerTWITS
Oct 5, 11:02 AM
$CELC David Gryska, Celcuity’s CFO, has one hell of a biotech résumé.
Companies where Gryska served as CFO or director were ultimately involved in acquisitions valued at roughly
$127 BILLION:
$CELG Celgene:
$74B
$SGEN Seagen:
$43B
$GWPH GW Pharmaceuticals:
$7.2B
$SOSI Scios:
$2.4B
$AERI Aerie Pharmaceuticals: ~
$770M
$CPWY Cardiac Pathways: ~
$115M
Gryska was CFO of Scios and Celgene and served on Seagen’s board from 2005 all the way through Pfizer’s
$43B acquisition.
Now he’s CFO of
$CELC, as Celcuity transitions from clinical-stage biotech to a commercial oncology company with an FDA-approved drug and additional indications in development.
Does this mean
$CELC gets acquired? No. But having a CFO with this level of biotech finance, board and M&A experience at the table certainly doesn’t hurt.
The résumé speaks for itself.
1 replies
